Current Drug Regulatory Status of Advanced Drug Evaluation System in Korea

被引:0
|
作者
Pork I.-S. [1 ]
Kim D.S. [2 ]
机构
[1] Pharmaceutical Standardization and Cardiovascular Drug Division, Drug Evaluation Department, Korea Food and Drug Administration, Seoul
[2] Toxicological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, 122-70, 194 Tongiro, Eunpyeong-gu
关键词
CTD; Drug approval; GMP; GRP; IND; KFDA; Korea;
D O I
10.1177/009286150904300108
中图分类号
学科分类号
摘要
The pharmaceutical industry is a high-risk and high value-added industry, because the risk of failure in research and development is considerable. However, successful development will allow a company to get high returns. The market scale of the pharmaceutical industry has been increasing in the world and the Korean market is changing to focus on quality of life drugs owing to people's increased income levels and changing lifestyles. Drug products are important for the prevention, diagnosis, and treatment of diseases, and the development of drug products has resulted in improved quality of life, health maintenance, and considerable benefits to individuals as well as the national economy. However, since drug products carry the risks of adverse reactions, they have to satisfy the two important criteria of safety and efficacy. Therefore, the Korean government has implemented a drug safety management system, including one for authorization of drug products. Recently, one of the most important issues in the Korean pharmaceutical industry has been the signing of the Korea-US FTA (Free Trade Agreement), which will promote rapid and widespread competition. The pharmaceutical industry will also face the challenges of a more competitive environment. For sustainable growth and development of the Korean pharmaceutical industry in this rapidly changing environment, the balanced harmonization of the industry's strategic R&S efforts and the government's positive policies is essential. © 2009, Drug Information Association. All rights reserved.
引用
收藏
页码:41 / 46
页数:5
相关论文
共 50 条
  • [41] THE DRUG REGULATORY SYSTEM - REFLECTIONS AND PREDICTIONS
    CROUT, JR
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1981, 15 (10): : 793 - 798
  • [42] Safety evaluation for new drug approval in Korea
    Kim, YO
    Ha, KW
    Choi, KS
    DRUG INFORMATION JOURNAL, 2001, 35 (01): : 285 - 291
  • [43] Immunotoxicity evaluation and guidelines for drug approval in Korea
    Kim, YO
    Chung, H
    Kil, KS
    Park, JH
    Kim, DS
    Cho, DH
    DRUG INFORMATION JOURNAL, 2000, 34 (01): : 25 - 32
  • [44] Immunotoxicity Evaluation and Guidelines for Drug Approval in Korea
    Young-Ok Kim
    Hyejoo Chung
    Kwang-Sup Kil
    Jae-Hyun Park
    Dong-Sup Kim
    Dae-Hyun Cho
    Drug information journal : DIJ / Drug Information Association, 2000, 34 : 25 - 32
  • [45] Safety Evaluation for New Drug Approval in Korea
    Young-Ok Kim
    Kwang-Won Ha
    Kwang-Sik Choi
    Drug information journal : DIJ / Drug Information Association, 2001, 35 (1): : 285 - 291
  • [46] Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends
    Liu, Qi
    Ahadpour, Mitra
    Rocca, Mitra
    Huang, Shiew-Mei
    AAPS JOURNAL, 2021, 23 (03):
  • [47] Clinical Pharmacology Regulatory Sciences in Drug Development and Precision Medicine: Current Status and Emerging Trends
    Qi Liu
    Mitra Ahadpour
    Mitra Rocca
    Shiew-Mei Huang
    The AAPS Journal, 23
  • [48] The current status of the emergency medical system in Korea
    Hwang, Sung Oh
    Lee, Christopher C.
    Singer, Adam J.
    Kim, Tae Min
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2007, 25 (07): : 846 - 848
  • [49] Advanced Drug Delivery Nanosystems: Perspectives and Regulatory Issues
    Demetzos, Costas
    GENEDIS 2014: NEURODEGENERATION, 2015, 822 : 195 - 198
  • [50] Current advanced bioluminescence technology in drug discovery
    Hoshino, Hideto
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (04) : 373 - 389